BMI1基因在髓系白血病中的表达及其对预后的影响。

BMI1 gene expression in myeloid leukemias and its impact on prognosis.

作者信息

Saudy Niveen S, Fawzy Iman M, Azmy Emad, Goda Enas F, Eneen Asmaa, Abdul Salam Eman M

机构信息

Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Laboratory Medicine Department, Mansoura Fever Hospital, Ministry of Health, Mansoura, Egypt.

出版信息

Blood Cells Mol Dis. 2014 Dec;53(4):194-8. doi: 10.1016/j.bcmd.2014.07.002. Epub 2014 Jul 30.

DOI:10.1016/j.bcmd.2014.07.002

PMID:25084695

Abstract

BACKGROUND

BMI1 is a polycomb group (PcG) protein and is overexpressed in leukemia. It plays a key role in the self-renewal of stem cells. Leukemic cells lacking BMI1 underwent proliferation arrest and showed signs of differentiation and apoptosis.

AIM

This study was aimed to investigate the expression and impact of BMI1 in myeloid leukemias. Expression levels of BMI1 in 100 acute myeloid leukemia (AML), 100 chronic myeloid leukemia (CML) patients and 20 healthy controls were measured by real time quantitative polymerase chain reaction (RQ-PCR).

RESULTS

The results showed that the expression of BMI1 was significantly higher in AML and CML versus control subjects (p<0.001 for both). The 2-year overall and disease free survival rates were significantly lower in patients expressing higher BMI1. Multivariate analysis showed that BMI1 was independent prognostic factor for OS for AML cases (p=0.015, HR=3.204, 95% CI=1.250-8.212). Accelerated and blastic phases in CML cases expressed higher BMI1 than chronic phase (p<0.001).

CONCLUSION

We concluded that detecting BMI1 is helpful for predicting the survival in AML patients and monitoring the aggressiveness and progression in patients with CML.

摘要

背景

BMI1是一种多梳蛋白家族（PcG）蛋白，在白血病中过表达。它在干细胞自我更新中起关键作用。缺乏BMI1的白血病细胞会发生增殖停滞，并表现出分化和凋亡迹象。

目的

本研究旨在调查BMI1在髓系白血病中的表达及影响。通过实时定量聚合酶链反应（RQ-PCR）检测100例急性髓系白血病（AML）、100例慢性髓系白血病（CML）患者及20例健康对照者中BMI1的表达水平。

结果

结果显示，AML和CML患者中BMI1的表达显著高于对照者（两者p均<0.001）。BMI1表达较高的患者2年总生存率和无病生存率显著较低。多因素分析显示，BMI1是AML患者总生存期的独立预后因素（p=0.015，HR=3.204，95%CI=1.250-8.212）。CML患者加速期和急变期的BMI1表达高于慢性期（p<0.001）。